A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients
Clin. transl. oncol. (Print)
; 19(11): 1350-1357, nov. 2017. tab, ilus, graf
Artigo
em Inglês
| IBECS
| ID: ibc-167116
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Purpose. Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Methods. Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. Results. The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p < 0.05). CD133 was expressed in 69 (96%) patients. The median CD133+ expression in circulating tumor cells CTCs was higher among the 21 AR-V7 positive cases versus AR-V7 negative (7 vs. 3). Androgen Receptor and PTEN fluorescence in situ hybridization (FISH) on CD133+ captured cells were performed 37 cases showed ≥four CD133+ CTCs, of which 81% showed an increased AR copy number. This percentage was similar in both AR-V7-positive and AR-V7-negative patients. A total of 68% of the cases showed deletion of PTEN 70% were ARV-7 positive vs. 67%, which were AR-V7 negative. Conclusions. Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors (AU)
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Próstata
/
Receptores Androgênicos
/
Neoplasias de Próstata Resistentes à Castração
/
Células Neoplásicas Circulantes
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2017
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complejo Asistencial Nuestra Señora de Sonsoles/Spain
/
Hospital Universitario de Salamanca/Spain
/
Institute of Biomedical Research of Salamanca (IBSAL)/Spain
/
Spanish National Cancer Research Centre (CNIO)/Spain